A recent hearing before Germany’s federal parliament has drawn renewed attention to the development, approval, and long-term monitoring of COVID-19 vaccines, highlighting the ongoing tension between urgent public health responses and scientific scrutiny.
On March 19, 2026, Dr. Helmut Sterz, identified in the proceedings as a former toxicologist associated with pharmaceutical work, delivered testimony before the Bundestag’s Corona Enquete Commission. His remarks centered on concerns about the pace of vaccine development during the height of the pandemic, arguing that certain long-term risk assessments, including carcinogenicity studies, were not completed prior to widespread public rollout. He attributed this to the intense time pressure faced by global health authorities and manufacturers during the emergency phase of the pandemic.
Sterz also raised questions about manufacturing processes, stating that large-scale production methods introduced residual bacterial DNA into vaccine batches. He characterized the broader vaccination campaign as a “tragedy” and referenced estimates suggesting tens of thousands of excess deaths in Germany, which he implied may be associated with vaccination efforts.
However, the hearing itself underscored that these claims remain contested within both scientific and regulatory communities. Germany’s Federal Minister of Health, Karl Lauterbach, addressed Sterz’s testimony directly during the same session, rejecting the assertions. Lauterbach stated that COVID-19 vaccines underwent extensive safety evaluations and that available data do not support claims of increased mortality, cancer incidence, infertility, or neurological disease linked to vaccination.
Regulatory bodies across Europe have consistently maintained that vaccine manufacturing and quality control processes include strict safeguards. The European Medicines Agency has explained that while mRNA vaccines are produced using plasmid DNA templates, any residual DNA fragments present in final doses are minimal, fragmented, and fall within established safety thresholds. According to the agency, there has been no verified evidence connecting such residual material to adverse health outcomes.
Similarly, Germany’s Paul-Ehrlich-Institut, which oversees vaccine approval and batch release, has reported that all COVID-19 vaccine lots distributed within the country were tested for compliance with strict specifications, including limits on residual DNA. The institute has stated that no correlation has been identified between these trace components and reported side effects.
The broader scientific framework also provides important context for the debate raised in the hearing. Standard vaccine development protocols do not always require long-term carcinogenicity studies for traditional vaccine platforms, particularly when the biological mechanisms involved do not indicate a plausible cancer risk. This approach has been reflected in international guidance, including recommendations from global health authorities during the pandemic.
Independent research conducted after vaccine rollout has further contributed to the evidence base. Studies examining multiple vaccine batches have found residual DNA levels to be below regulatory limits and composed of small, degraded fragments rather than intact genetic material capable of biological integration. Public health agencies have also emphasized ongoing pharmacovigilance systems designed to detect rare or long-term adverse effects, with no confirmed signals indicating widespread harm of the type suggested in Sterz’s testimony.
At the population level, the impact of COVID-19 vaccination campaigns continues to be evaluated through large-scale epidemiological studies. Findings from international health organizations indicate that vaccines significantly reduced severe illness, hospitalizations, and deaths during successive waves of the pandemic, particularly among vulnerable populations.
The Bundestag hearing reflects a broader reality in post-pandemic society: scientific debates that were once largely confined to academic settings are now playing out in public and political arenas. While dissenting voices such as Sterz’s contribute to ongoing scrutiny, they also highlight the importance of distinguishing between individual testimony and the broader consensus built from accumulated evidence.
As governments and health authorities continue to assess lessons learned from the pandemic, discussions like these are likely to shape future policies on emergency approvals, transparency, and long-term monitoring. For the public, the challenge remains navigating complex and sometimes conflicting claims while relying on verifiable data and established scientific processes to inform understanding.